Riviciclib hydrochloride

• UNSPSC Description:

  Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively[1][2]. Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells[3].

• Target Antigen:

  Apoptosis; CDK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Riviciclib_hydrochloride.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)|H2O : 25 mg/mL (ultrasonic)

• Smiles:

  [H]Cl.O=C1C=C(C2=CC=CC=C2Cl)OC3=C([C@@H]4CCN(C)[C@H]4CO)C(O)=CC(O)=C31

• Molecular Weight:

  438.307

• References & Citations:

  [1]Roskoski R Jr,Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.Pharmacol Res. 2016 May;107:249-275.|[2]Joshi KS, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007 Mar;6(3):918-25.|[3]Joshi KS,et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.Elife. 2020 Dec 7;9:e61405.|Pharmaceuticals. 2024 Apr 29, 17(5), 569.|Int J Mol Sci. 2022 Feb 24;23(5):2493.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 2

• CAS Number:

  920113-03-7